Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Keros Therapeutics Q4 EPS $(1.09) Beats $(1.10) Estimate

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.10) by 0.91 percent. This is a 263.33 percent decrease over losses of $(0.30) per share
byHappy Mohamed
March 3, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.10) by 0.91 percent. This is a 263.33 percent decrease over losses of $(0.30) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Recap: F5 Q2 Earnings

By Benzinga Insights
Today, 2:02 AM
F5 (NASDAQ:FFIV) reported its Q2 earnings results on Tuesday, April 26, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings F5 beat estimated earnings by 5.97%, reporting an EPS of $2.13 versus an estimate of $2.01.

FFIV